This website is for healthcare providers

Please click on the agreement button below to acknowledge that you are a healthcare provider.

You Have Options

Introducing Liqrev® (sildenafil) and Tadliq® (tadalafil)
for treating patients with Pulmonary Arterial Hypertension (PAH)

Click the tabs below for treatment options

Have questions? Call CMP Support Services
1-844-267-0001
Download Prescription Request Form
Menu

FDA-approved Ready-made Oral Suspension of Sildenafil

Do You Know The Risks of Crushing/Compounding?

Liqrev® is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.

Available in: 122 mL bottle

ABOUT LIQREV

For adult patients with issues swallowing, Liqrev® is the only FDA-approved oral liquid suspension of Sildenafil for treating Pulmonary Arterial Hypertension (PAH).

  • FDA-approved and ready-made for immediate use: just shake and dispense
  • Eliminates preparation of powder formulations
  • Removes risks associated with unapproved compounded formulations
background illustration

The Right Medication for the Right Patient

Choosing Liqrev ensures patient safety, is convenient, and requires no preparation by a pharmacist. Compare Liqrev with other common PAH formulations below.

Liqrev® (Sildenafil) Oral Suspension Crushed & Compounded Tadalafil/Sildenafil Tablets Sildenafil Powder
FDA-approved oral liquid formulation: Yes No Only after powder has been properly reconstituted by a pharmacist.
Ready made minimal preparation: Yes. Shake & dispense No No. Time consuming 10-step process that must be performed by a pharmacist.
Liquid Formulation is FDA tested to ensure potency, efficacy & safety: Yes No Only after powder has been properly reconstituted by a pharmacist.
Shelf life of liquid formulation: 24 months Unknown 60 days

Liqrev Educational Resources

Dysphagia & The Need For Liquid Alternatives

Patients with pulmonary arterial hypertension (PAH) may also suffer from dysphagia, the medical term used to describe difficulty swallowing. Co-morbidities are often a factor in the prevalence of dysphagia. For instance, scleroderma is a co-morbid condition that can affect up to 40% of PAH patients.1 Scleroderma presents with significant gastrointestinal involvement commonly in the esophagus, leading to dysphagia.

Dysphagic Patients:

Dysphagia can include difficulty starting a swallow (oropharyngeal dysphagia), issues in the throat (pharyngeal dysphagia), and the sensation of food being stuck (esophageal dysphagia). Given these complications it’s important to optimize treatment plans for these patients.

Unfortunately, liquids derived from crushed/compounded tablets raise concerns about patient safety and efficacy, and they have come under increasing scrutiny from the FDA.

Patients Who Have
Difficulty Swallowing

Patients who need a liquid formulation may
also have a comorbid condition that
creates difficulty swallowing.

“Compounded drugs should only be distributed to meet the needs of patients whose medical needs cannot be met by an FDA-approved drug”

Scott Gottlieb, MD: Former FDA Commissioner

READ THIS BEFORE YOU CRUSH/COMPOUND ANOTHER TABLET

THE RISKS AND CONCERNS OF CRUSHING/COMPOUNDING

Patients who have difficulty swallowing are often given crushed/compounded formulations of the prescriptions. However, crushed/compounded formulations can exhibit a wide variation in potency due to non-uniformity of compounded materials. These dosing inconsistencies of compounded suspensions have long been a persistent challenge for pharmacists and patients.3

Crushed/compounded formulations are not tested for safety or efficacy.

Due to fatalities related to contamination, the FDA recently released stricter guidance regarding crushing/compounding and recommended against using crushed/compounded products considered “essentially copies of a commercially available drug product” without permission, especially if an FDA-approved alternative exists.4

 

1. Pulmonary Hypertension in Scleroderma. University of Michigan Health. Accessed September 19, 2022. https://www.uofmhealth.org/conditions-treatments/rheumatology/pulmonary-hypertension-scleroderma 2. Gudeman, Jennifer, Michael Jozwiakowski, John Chollet, and Michael Randell. “Potential Risks of Pharmacy Compounding.” Drugs in R&D 13, no. 1 (2013): 1-8. doi:10.1007/s40268-013-0005-9. 3. Kindy K, Sun L, Crites A. Compounding pharmacies have been linked to deaths, illnesses for years. Washington Post. February 7, 2013. 4. Food Drug Administration Center for Drug Evaluation & Research (2016). Guidance for Industry: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDA, Maryland) 1-8. doi:10.1007/s40268-013-0005-9.

Prescribing Liqrev

CMP Support Services is here to help

CMP Support Services is here to support both physicians and patients with accessing Liqrev by providing the following:

  • Verifying benefits & securing insurance coverage for Liqrev
  • Providing updates to the prescriber during each step of the process
  • Identifying commercially eligible patients that may qualify for co-pay assistance*
  • Submitting the prescription to the specialty pharmacy provider to dispense Liqrev

How to Prescribe:

Option 1: CMP Support Services

  1. Download a Liqrev prescription form at liqrev.com/form or get a paper copy mailed to you by calling us at (844) 267-0001.
  2. Fax the completed form to CMP Support Services at (844) 267-0020.

Download Prescription Request Form

Option 2: Direct to Specialty Pharmacy

  1. Download a Liqrev prescription form at liqrev.com/specialty
  2. Complete the entire form and fax to a specialty pharmacy or submit via an e-Prescribing platform.

Download Specialty Prescription Form

Commercially insured patients may pay as little as $0* on each prescription with the EasyPay Copay Program

Call CMP Support Services toll-free (844) 267-0001

Mon-Friday 8am-5pm ET

* Void where prohibited by law. CMP Pharma reserves the right to rescind, revoke or amend this program without notice. Offer not valid for patients eligible for benefits under Medicaid (including Medicaid managed care), Medicare, TRICARE, Veterans Affairs, FEHBP, or similar state or federal programs. Offer void where prohibited, taxed, or otherwise restricted. Offer good only in the U.S.A. No generic substitution with this offer.

Get an EasyPay Card

Important Safety Information

INDICATIONS AND USAGE

Adults

LIQREV is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.

Pediatric use information is approved for Viatris Specialty LLC’s, REVATIO (sildenafil) tablets. However, because of Viatris Specialty LLC’s marketing exclusivity rights, this drug product is not labeled with that information.

CONTRAINDICATIONS

LIQREV is contraindicated in patients with:

  • Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension.
  • Concomitant use of riociguat, a guanylate cyclase stimulator. PDE-5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.
  • Known hypersensitivity to sildenafil or any component of the oral suspension. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil.

Warnings And Precautions

  • Vasodilation effects may be more common in patients with hypotension or on antihypertensive therapy.
  • Use in pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema and is not recommended.
  • Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs.
  • Pulmonary hypertension (PH) secondary to sickle cell disease: LIQREV may cause serious vaso-occlusive crises.

Adverse Reactions

Adults: Headache, dyspepsia, flushing, pain in limb, myalgia, back pain, and diarrhea

To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

  • Nitrates – Concomitant use of LIQREV with nitrates in any form is contraindicated.
  • Strong CYP3A Inhibitors – Concomitant use of LIQREV with strong CYP3A inhibitors is not recommended.
  • Moderate-to-Strong CYP3A Inducers – Concomitant use of LIQREV with moderate-to-strong CYP3A inducers (such as bosentan) decreases the sildenafil exposure.
  • Concomitant PDE-5 inhibitors – Avoid use with VIAGRA or other PDE-5 inhibitors.

Dosage And Administration

Recommended Dosage in Adults – The recommended dosage of LIQREV is 20 mg orally three times a day. A calibrated measuring device is recommended to measure and deliver the prescribed dose accurately. Shake well for at least 10 seconds before use.

Pediatric use information is approved for Viatris Specialty LLC’s, REVATIO (sildenafil) tablets. However, because of Viatris Specialty LLC’s marketing exclusivity rights, this drug product is not labeled with that information.

Please see Prescribing Information for additional safety information.

Liqrev® and the stylized Liqrev® logo are registered trademarks of CMP Development LLC. Liqrev is marketed by CMP Pharma, Inc. © 2023 CMP Pharma, Inc. All rights reserved.

Indication

Liqrev® is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.

Contraindications

  • Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension.
  • Concomitant use of riociguat, a guanylate cyclase stimulator. PDE-5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.
  • Known hypersensitivity to sildenafil or any component of the oral suspension. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil.
See More